Factors affecting prostate cancer detection through asymptomatic prostate-specific antigen testing in primary care in England: evidence from the 2018 National Cancer Diagnosis Audit

被引:0
作者
Merriel, Samuel W. D. [1 ]
Akter, Nurunnahar [2 ,3 ]
Zakkak, Nadine [4 ,5 ]
Swann, Ruth [5 ]
Mcphail, Sean [6 ]
Rubin, Greg [7 ]
Lyratzopoulos, Georgios [8 ]
Abel, Gary [9 ]
机构
[1] Univ Manchester, Natl Inst Hlth & Care Res Acad Clin Lecturer, Ctr Primary Care & Hlth Serv Res, Manchester, England
[2] Univ Exeter, Exeter Collaborat Acad Primary Care APEx, Exeter, Devon, England
[3] Univ Liverpool, Dept Hlth Data Sci, Liverpool, England
[4] UCL, London, England
[5] Canc Res UK, London, England
[6] Natl Canc Registrat & Anal Serv, NHS Digital, London, England
[7] Newcastle Univ, Newcastle, England
[8] UCL, London, England
[9] Univ Exeter, Med Stat & Hlth Serv Res, APEx, Exeter, England
关键词
asymptomatic; primary health care; prostate; prostate cancer; prostate-specific antigen;
D O I
10.3399/BJGP.2024.0376
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Prostate-specific antigen (PSA) is used in primary care for prostate cancer detection, either for symptomatic assessment or asymptomatic testing following an informed decision. Aim To estimate the proportion of patients with prostate cancer who were diagnosed following asymptomatic PSA testing, and the patient and practice factors influencing this route. Design and setting The 2018 English National Cancer Diagnosis Audit (NCDA) data were analysed, with linkage to the National Cancer Registration and Analysis Service, practice-level Quality and Outcomes Framework (QOF), and GP Patient Survey (GPPS) data. All 2018 NCDA patients with a diagnosis of prostate cancer were included (n = 9837). Method Patients with recorded biomarker testing and no recorded symptoms before diagnosis were classified as having asymptomatic PSA-detected prostate cancer. Patient (age, ethnicity, deprivation, and comorbidities) and practice (geographical location, area deprivation, list size, urgent suspected cancer referral rate, QOF outcomes, and GPPS results) factors were analysed for association with asymptomatic PSA testing using mixed-effects logistic regression models. Results In total, 1884 out of 9837 (19.2%) patients with prostate cancer were detected following asymptomatic PSA testing, 982 (52.1%) of whom were aged 50-69 years. Younger age, non-White ethnicity, lower deprivation, and lower comorbidity count were associated with an increased likelihood of diagnosis following asymptomatic PSA testing. There was a 13-fold variation between practices in the odds of detecting prostate cancer through asymptomatic PSA testing, without clear explanatory practice-level factors. Conclusion One in five patients with prostate cancer in England are diagnosed after asymptomatic PSA testing in primary care, with large variation in asymptomatic PSA detection between practices.
引用
收藏
页码:e300 / e305
页数:6
相关论文
共 24 条
[1]   Prostate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998-2017 [J].
Clift, Ashley Kieran ;
Coupland, Carol A. C. ;
Hippisley-Cox, Julia .
BRITISH JOURNAL OF GENERAL PRACTICE, 2021, 71 (703) :E157-E165
[2]   Opportunistic prostate-specific antigen screening in Italy: 6 years of monitoring from the Italian general practice database [J].
D'Ambrosio, Gaetano Giorgio ;
Campo, Salvatore ;
Cancian, Maurizio ;
Pecchioli, Serena ;
Mazzaglia, Giampiero .
EUROPEAN JOURNAL OF CANCER PREVENTION, 2010, 19 (06) :413-416
[3]  
Department of Health and Social Care, 2024, NATL GEN PRACTICE PR
[4]  
Department of Health and Social Care, 2024, CANC SERVICES
[5]   Opportunistic Testing Versus Organized Prostate-specific Antigen Screening: Outcome After 18 Years in the Goteborg Randomized Population-based Prostate Cancer Screening Trial [J].
Godtman, Rebecka Arnsrud ;
Holmberg, Erik ;
Lilja, Hans ;
Stranne, Johan ;
Hugosson, Jonas .
EUROPEAN UROLOGY, 2015, 68 (03) :354-360
[6]   Association of sociodemographic factors and prostate-specific antigen (PSA) testing [J].
Gorday, William ;
Sadrzadeh, Hossein ;
de Koning, Lawrence ;
Naugler, Christopher .
CLINICAL BIOCHEMISTRY, 2014, 47 (16-17) :164-169
[7]   Prostate cancer screening in Switzerland: 20-year trends and socioeconomic disparities [J].
Guessous, Idris ;
Cullati, Stephane ;
Fedewa, Stacey A. ;
Burton-Jeangros, Claudine ;
Courvoisier, Delphine S. ;
Manor, Orly ;
Bouchardy, Christine .
PREVENTIVE MEDICINE, 2016, 82 :83-91
[8]  
Healthcare Quality Improvement Partnership, 2022, PAT TUM CHAR ASS MET
[9]   The diagnostic impact of UK regional variations in age-specific prostate-specific antigen guidelines [J].
Light, Alexander ;
Burns-Cox, Nicholas ;
Maccormick, Angus ;
John, Joseph ;
McGrath, John ;
Gnanapragasam, Vincent J. .
BJU INTERNATIONAL, 2021, 128 (03) :298-300
[10]   Diagnosis of prostate cancer in primary care: navigating updated clinical guidance [J].
Merriel, Samuel W. D. ;
Seggie, Andrew ;
Ahmed, Hashim .
BRITISH JOURNAL OF GENERAL PRACTICE, 2023, 73 (727) :54-55